secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001558370-23-020006
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix updates on Elfabrio approvals, PRX-115 Phase I progress, and pipeline
------------------------------------------------------------------------------

- Elfabrio (Fabry disease) approved by FDA and EMA; launched in US, EU, UK via Chiesi partnership.
- Phase I trial of PRX-115 (gout) completed 7th cohort with 56 patients dosed; completion expected Q2 2024.
- Preclinical development advancing for PRX-119 (DNase I for NETs-related diseases).
- CEO acknowledges ongoing challenges in Israel, reaffirms commitment to operations and pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023020006/0001558370-23-020006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023020006/plx-20231226x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-020006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer